Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel C Mok

Showing results (71-80 of 144) with videos related to

Pageof 15
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2008
Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patientsAudrey Gagnon, Jae-Hoon Kim, John O Schorge, et al.
Neoplasia (New York, N.Y.)|June 2, 2009
Inflammatory cytokine tumor necrosis factor alpha confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cellsJoseph Kwong, Franky Leung Chan, Kwong-kwok Wong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analysesHiroshi Tsuda, Yoichi M Ito, Yasuo Ohashi, et al.
Gynecologic Oncology|June 27, 2013
Poor survival with wild-type TP53 ovarian cancer?Kwong-Kwok Wong, Daisy I Izaguirre, Suet-Yan Kwan, et al.
Cancer Prevention Research (Philadelphia, Pa.)|February 1, 2011
Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesisMelinda S Yates, Larissa A Meyer, Michael T Deavers, et al.
Neoplasia (New York, N.Y.)|February 22, 2005
Epigenetic silencing of cellular retinol-binding proteins in nasopharyngeal carcinomaJoseph Kwong, Kwok-Wai Lo, Lillian Shuk-Nga Chow, et al.
Cancer|December 12, 2003
Prostate carcinoma tissue proteomics for biomarker discoveryYaxin Zheng, Ye Xu, Bin Ye, et al.
The Journal of Pathology|February 20, 2014
KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinomaYvonne T Tsang, Michael T Deavers, Charlotte C Sun, et al.
Molecular Cancer Therapeutics|December 21, 2002
Relationship of XIST expression and responses of ovarian cancer to chemotherapyKuan-Chun Huang, Pulivarthi H Rao, Ching C Lau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2007
Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomasMichael J Birrer, Michael E Johnson, Ke Hao, et al.
Pageof 15

Showing results (71-80 of 144) with videos related to

Sort By:
Pageof 15
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2008
Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patientsAudrey Gagnon, Jae-Hoon Kim, John O Schorge, et al.
Neoplasia (New York, N.Y.)|June 2, 2009
Inflammatory cytokine tumor necrosis factor alpha confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cellsJoseph Kwong, Franky Leung Chan, Kwong-kwok Wong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analysesHiroshi Tsuda, Yoichi M Ito, Yasuo Ohashi, et al.
Gynecologic Oncology|June 27, 2013
Poor survival with wild-type TP53 ovarian cancer?Kwong-Kwok Wong, Daisy I Izaguirre, Suet-Yan Kwan, et al.
Cancer Prevention Research (Philadelphia, Pa.)|February 1, 2011
Microscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesisMelinda S Yates, Larissa A Meyer, Michael T Deavers, et al.
Neoplasia (New York, N.Y.)|February 22, 2005
Epigenetic silencing of cellular retinol-binding proteins in nasopharyngeal carcinomaJoseph Kwong, Kwok-Wai Lo, Lillian Shuk-Nga Chow, et al.
Cancer|December 12, 2003
Prostate carcinoma tissue proteomics for biomarker discoveryYaxin Zheng, Ye Xu, Bin Ye, et al.
The Journal of Pathology|February 20, 2014
KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinomaYvonne T Tsang, Michael T Deavers, Charlotte C Sun, et al.
Molecular Cancer Therapeutics|December 21, 2002
Relationship of XIST expression and responses of ovarian cancer to chemotherapyKuan-Chun Huang, Pulivarthi H Rao, Ching C Lau, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2007
Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomasMichael J Birrer, Michael E Johnson, Ke Hao, et al.
Pageof 15